- Harsha Deshmukh has been appointed a member of the Board of Managing Directors with responsibility for IT and Global Business Services effective 1 February 2026
Boehringer Ingelheim announced today that the Shareholders’ Committee has appointed Harsha Deshmukh to the Board of Managing Directors. Effective 1 February 2026, Harsha Deshmukh will lead the IT and Global Business Services functions focusing on digital transformation and driving the further development of business services at the company. IT and Global Business Services, which so far were part of the Group Functions Division, will be set up as a separate Board Division.

Commenting on the appointment, Hubertus von Baumbach, Chairman of the Boehringer Shareholders’ Committee said: “We warmly welcome Harsha Deshmukh. With his extensive experience in fostering innovation, he will help drive our journey of transformation – a transformation in the interest of patients. We know that in this process of continuous improvement we can rely on the proven skills, the contributions and the high commitment of each individual in our organization.”
Chairman of the Board of Managing Directors Shashank Deshpande added: “I am excited to welcome Harsha to Boehringer Ingelheim. His appointment strengthens our capabilities in the important segments of IT and services, two areas that are critical elements to underpin our future growth.”
Harsha Deshmukh will join Boehringer Ingelheim from Infineon Technologies AG in Munich, where he most recently was Executive Vice President & Chief Information Officer. He holds degrees in Electronics, Human Resources and Global Management from the University of Mumbai, Babson College and INSEAD.
Harsha Deshmukh
Diploma Engineering and Industrial Electronics, MBA Human Resources Management (University of Mumbai), Global Management (Babson College and INSEAD)
Professional milestones
2021 – present Executive Vice President & Chief Information Officer, Infineon Technologies AG, Munich, Germany
2009 – 2021 Senior Vice President Information Technology, Infineon Technologies AG, Munich, Germany
2001 – 2009 Director of Supply Chain Applications, Infineon Technologies, Munich, Germany
1999 – 2001 Senior Consultant Advanced Planning Systems, Siemens Information Management Systems, Mumbai, India
1989 – 1999 Manager Manufacturing Automation, Mukand Ltd., Mumbai, India
About Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at www.boehringer-ingelheim.com.
Attachment
-
再获殊荣!A.O.史密斯AI-LiNK摘得“磐石奖·品质创新奖”在刚刚落幕的2025(第十五届)中国家电营销年会上,A.O.史密斯AI-LiNK数字真五恒集成系统凭借卓越的技术创新与全链路服务保障,从众多参赛产品中脱颖而出,成功摘得“磐石2025-11-30
-
弦高城·2025婺源马拉松收官,八千余名跑者逐梦“中国最美乡村”初冬时节的婺源,暖阳如绘,诗意正浓。11月30日上午8时,弦高城·2025婺源马拉松在文化广场热力启幕。来自全国各地的八千余名跑者齐聚“中国最美乡村”,于斑斓山色与潋2025-11-30
-
武汉百联奥莱年度感恩季 承接新消费势能 推动城市年末消费增长随着消费结构持续迭代,武汉正迈向建设国际消费中心城市新阶段。作为华中区域奥莱标杆,武汉百联奥莱在这个感恩季持续引入新场景、新互动与新体验,通过跨界内2025-11-30
-
武汉百联奥莱年度感恩季 承接新消费势能 推动城市年末消费增长随着消费结构持续迭代,武汉正迈向建设国际消费中心城市新阶段。作为华中区域奥莱标杆,武汉百联奥莱在这个感恩季持续引入新场景、新互动与新体验,通过跨界内2025-11-30
-
歌礼选定其首款口服GLP-1RGIPRGCGR三靶点激动剂多肽ASC37进行临床开发- 在非人灵长类动物的头对头研究中,通过利用歌礼口服多肽递送增强技术(POTENT),ASC37口服片的平均绝对口服生物利用度达4.2%,分别约为采用口服 SNAC制剂技术的司美格鲁2025-11-30
